DEFA14A: Hologic Acquired by Blackstone & TPG for $79/Share

Hologic, Inc. announced an agreement to be acquired by Blackstone and TPG for up to $79 per share, aiming for accelerated growth and global expansion.

Summary

• Hologic, Inc. has agreed to be acquired by Blackstone and TPG for up to $79 per share.
• The acquisition is expected to close in the first half of calendar year 2026.
• The transaction is subject to customary closing conditions, including stockholder and regulatory approvals.
• Hologic will continue to operate as a standalone, publicly listed company until the transaction closes.
• The partnership is anticipated to provide additional resources, capital, and capabilities to improve women's health globally.
• Expected benefits include continued support for product trajectory, accelerated pipeline development, broadened international reach, and strengthened capacity for strategic acquisitions.

Sentiment

Score: 9

Explanation: The filing announces a definitive agreement for acquisition at a specific price, framed with overwhelmingly positive language by management, highlighting significant strategic benefits and growth opportunities under new ownership.

Positives

• The acquisition by Blackstone and TPG is expected to provide Hologic with additional resources, capital, and capabilities.
• The partnership aims to accelerate Hologic's product pipeline and broaden its international reach.
• Hologic anticipates strengthened capacity for strategic acquisitions under new ownership.
• Blackstone and TPG are committed to supporting Hologic's mission in women's health and believe in the company's people and products.
• The acquiring firms have a long and successful track record of partnering with innovative healthcare companies to advance their missions and enable growth.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay or cause the abandonment of the proposed transaction.
• There is a risk of the merger agreement being terminated due to an event, change, or other circumstances.
• Hologic stockholders may not approve the proposed transaction.
• The parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• The proposed transaction could disrupt management time from ongoing business operations.
• Announcements related to the proposed transaction could have adverse effects on Hologic's common stock market price.
• There is a risk of unexpected costs or expenses resulting from the proposed transaction.
• Potential litigation relating to the proposed transaction.
• The transaction and its announcement could adversely affect Hologic's ability to retain and hire key personnel, maintain relationships with customers, vendors, partners, employees, and stockholders, and impact operating results and business generally.
• Holders of Contingent Value Rights (CVRs) may receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

The company anticipates continued support for its product trajectory, additional growth, acceleration of its pipeline, broadened international reach, and strengthened capacity for strategic acquisitions under the new ownership. The transaction is expected to close in the first half of calendar year 2026, subject to customary approvals.

Management Comments

• "I'm pleased to share important and exciting news that will position Hologic for an even stronger future and help us build on our mission to enable healthier lives everywhere, every day." Steve MacMillan, Chairman, President and CEO.
• "I believe this is excellent news for Hologic as a whole, and more specifically for our employees, customers, patients and stockholders." Steve MacMillan.
• "Blackstone and TPG are fully committed to supporting our Purpose, Passion and Promise." Steve MacMillan.
• "We will be even better positioned globally, with fewer capital constraints and more opportunities to pursue." Steve MacMillan.
• "Our Board of Directors, Global Leadership Team and I are incredibly proud of what we've accomplished, and firmly believe that now is the right time to take Hologic to the next level." Steve MacMillan.

Industry Context

This acquisition reflects a broader trend of private equity firms, such as Blackstone and TPG, investing in established healthcare companies with strong market positions and growth potential, particularly in specialized sectors like women's health and medical technology. Such partnerships often aim to provide capital and strategic support to accelerate innovation, expand market reach, and optimize operations away from public market scrutiny.

Comparison to Industry Standards

• The filing does not provide specific financial or operational results that can be directly compared to global industry benchmarks or specific comparable companies. The focus is on the acquisition terms and future strategic benefits rather than current performance metrics relative to peers.

Stakeholder Impact

• Shareholders: Expected to receive up to $79 per share, which is presented as excellent news.
• Employees: Anticipated continued support, growth opportunities, and alignment with new owners' cultures. However, there is a risk of adverse effects on the ability to retain and hire key personnel.
• Customers/Patients: Expected to benefit from improved women's health globally, accelerated product pipeline, and enhanced ability to deliver critical medical technologies.
• Vendors/Partners: Risk of adverse effects on maintaining relationships due to the transaction.

Next Steps

• The transaction is expected to close in the first half of calendar year 2026, pending stockholder and regulatory approvals.
• Hologic will continue to operate as a standalone, publicly listed company until the transaction closes.
• More information will be shared in the coming days.
• Opportunities will be provided to introduce employees to the Blackstone and TPG teams at the appropriate time.
• Resources will be provided to employees who interact with customers to help answer questions.
• Hologic will file a Proxy Statement with the SEC in connection with the proposed acquisition.

Key Dates

Recommendation

The company has announced a definitive agreement to be acquired for up to $79 per share. For existing shareholders, holding the stock until the expected closing in H1 2026 allows them to receive the acquisition price, assuming the deal successfully completes. Selling now would lock in any gains and mitigate the risks associated with the transaction not closing.

Keywords

Hologic, Blackstone, TPG, Acquisition, Merger, Women's Health, Medical Technology, Healthcare Investment, Corporate Governance, SEC Filing